You are here

Glycolysis and Parkinson’s Disease

Weekly Seminar | Not Open to the Public
Who Should Attend: 


I will review how our work mapping circuits of cognitive control in Parkinson’s disease might lead to targeted biomarkers and interventions. Next, I will describe our new collaborative efforts focused on glycolysis and metabolism in Parkinson’s disease. I will discuss our recent evidence from in vitro models, cell lines, animal models, and large retrospective databases describing how repurposed drugs that enhance glycolysis might lead to disease-modifying therapies for Parkinson’s disease.

Dr. Nandakumar Narayanan's Figure


Qiang Zhang, Matthew A Weber, Nandakumar S Narayanan
Medial prefrontal cortex and the temporal control of action
Int Rev Neurobiol. 2021;158:421-441. doi: 10.1016/bs.irn.2020.11.004. Epub 2020 Dec 15.
Arun Singh, Rachel C Cole, Arturo I Espinoza, Aron Evans, Scarlett Cao, James F Cavanagh, Nandakumar S Narayanan
Timing variability and midfrontal ~4 Hz rhythms correlate with cognition in Parkinson's disease
NPJ Parkinsons Dis. 2021 Feb 15;7(1):14. doi: 10.1038/s41531-021-00158-x.
Jacob E Simmering, Michael J Welsh, Lei Liu, Nandakumar S Narayanan, Anton Pottegård
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease
JAMA Neurol. 2021 Apr 1;78(4):407-413. doi: 10.1001/jamaneurol.2020.5157.


Tuesday, June 8, 2021 - 12:30pm


Conference Room: 
Online Webinar

More Information

Darlene White

Conditions & Recovery

Neurodegenerative Diseases icon
Worldwide, 50 million people are living with Alzheimer's and other dementias.